October 1 in Heidelberg
The ways in which we treat diseases are becoming more and more innovative, with the biotech industry demonstrating its full potential in the development of new ways to treat patients.
Our industry is constantly inventing, validating, and developing new drug modalities such as antibody-drug conjugates, RNA therapeutics, targeted degradation, gene editing, oligonucleotides and various combinations of these and other tools to address pathophysiological conditions.
Collaboration among industry, academia, regulatory, clinician and patient communities, as well as ad hoc funding and investment frameworks are essential to bring these solutions to the patients.
This year Annual Conference presents some of these biotechnology-driven new therapeutical approaches and partnership models for successful drug development.
Call for Poster is open!
When: 1. October 2021 9:00 - 17:00
Where: Halle02, Zollhofgarten 2, 69115 Heidelberg
AGENDA (9:00 - 17:00)
Welcome & introduction
Keynote: “Next generation Immunotherapy”
Holger Kissel, BioNTech SE, Vice President Business Alliances
Dirk Grimm, University of Heidelberg, Professor and Group Leader
“The fast and the curious – high-throughput in vitro and in vivo interrogation of
AAV capsid libraries”
Christiane Kofink, Boehringer Ingelheim RCV & CoKG, Vienna, Principal Scientist
“The discovery of the first selective and orally bioavailable SMARCA2 degrader BI-0284”
Ivan Đikić, Goethe University Frankfurt, Professor
“PROXIDRUGS: new therapeutic options for numerous diseases"
Claus Kremoser, WMT Therapeutics AG, Co-Founder and Chairman of the Board
“Targeting Cancer Metabolism to foster Immune Attack on Solid Tumours”
Michael Zimmermann, EMBL, Group Leader
“Identifying microbiome contributions to drug metabolism and toxicity”
“Futureproofing your Process Development” hosted by Cytiva.
How can you balance innovation, speed and robustness to accelerate your process development? Find out more in this workshop.
“Innovative technologies and statistical methods for successful drug development” hosted by Cytel.
Explore technological solutions which enables cross-functional teams to optimize speed, cost and probability of success in drug development. And discover which Bayesian approaches can be used from preclinical to post-authorization to support orphan drug development.
Keynote: “Development of Bulevirtide/Hepcludex®, the first approved medication to treat chronic Hepatitis D infections.”
Florian Vogel, MYR (Gilead Sciences Inc.), Chief Commercial Officer
Stephan Urban, Heidelberg University Hospital, Head of
the Translational Virology Unit
Happy Hour & Speed-Networking
The conference is an event organised for BioRN members, associated and friends.